APOA5

(redirected from Apolipoprotein A5)

APOA5

A gene on chromosome 11q23 that encodes apolipoprotein A-V, a minor apolipoprotein mainly associated with high-density lipoprotein (HDL), less so with VLDL and chylomicrons. It is an important determinant of plasma triglyceride (TG) levels, both stimulating TG hydrolysis by apo-CII lipoprotein lipase and inhibiting VLDL-TG production.
References in periodicals archive ?
Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor.
Apolipoprotein A5 (ApoA5) has been proposed to be a key regulator of serum triglyceride concentrations [for a complete review, see Refs.
Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice.
The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins.
Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans.
A single nucleotide polymorphism -1131T>C in the apolipoprotein A5 gene is associated with an increased risk of coronary artery disease and alters triglyceride metabolism in Chinese.
Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels.
It seems likely that the recently discovered apolipoprotein A5 (apo A5), the subject of the report by O'Brien et al.
Apolipoprotein A5 was finally identified following the discovery of an open-reading frame in the gene cluster for apolipoproteins A1-C3-A4, which did not correspond to any known apolipoprotein (29).
The recently discovered apolipoprotein A5 (ApoA5) [3] is rapidly being recognized as a key regulator of serum triglyceride concentrations [for a complete review, see Refs.
The single nucleotide polymorphism -1131T>C in the apolipoprotein A5 (ApoA5) gene is associated with elevated triglycerides in patients with hyperlipidemia.